Protagonist Therapeutics (PTGX) News Today $38.75 +0.26 (+0.68%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$39.89 +1.14 (+2.94%) As of 02/21/2025 06:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Protagonist Therapeutics, Inc. (NASDAQ:PTGX) CEO Sells $204,606.62 in StockProtagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) CEO Dinesh V. Ph D. Patel sold 5,359 shares of the company's stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $38.18, for a total transaction of $204,606.62. Following the completion of the transaction, the chief executive officer now directly owns 540,260 shares in the company, valued at approximately $20,627,126.80. The trade was a 0.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.February 21 at 8:50 PM | marketbeat.comProtagonist Therapeutics reports Q4 EPS $1.98 vs.44c last yearFebruary 21 at 4:15 PM | markets.businessinsider.comProtagonist Therapeutics sees cash runway through at least end of 2028February 21 at 4:15 PM | markets.businessinsider.comDinesh V. Ph D. Patel Sells 5,359 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) StockFebruary 21 at 6:50 AM | insidertrades.comHussman Strategic Advisors Inc. Purchases New Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Hussman Strategic Advisors Inc. acquired a new position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 105,000 sharesFebruary 21 at 6:37 AM | marketbeat.comProtagonist Therapeutics (PTGX) Gets a Buy from Truist FinancialFebruary 19 at 10:47 AM | markets.businessinsider.comProtagonist Therapeutics (PTGX) Projected to Post Quarterly Earnings on TuesdayProtagonist Therapeutics (NASDAQ:PTGX) will be releasing earnings before the market opens on Tuesday, February 25, Financial Modeling Prep reports.February 18, 2025 | marketbeat.comProtagonist Therapeutics' SWOT analysis: stock poised for growth amid clinical milestonesFebruary 17, 2025 | msn.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by AlphaCentric Advisors LLCAlphaCentric Advisors LLC decreased its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 71.5% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 7,123 shares of the company's stock after selling 17,877 shares during the period. AlpFebruary 17, 2025 | marketbeat.comBrokerages Set Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Price Target at $56.00February 14, 2025 | americanbankingnews.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Average Recommendation of "Buy" by BrokeragesProtagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) has earned an average rating of "Buy" from the nine research firms that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a hold recommendation, seven have assigned a buy recommendatFebruary 9, 2025 | marketbeat.comProtagonist Therapeutics participates in a conference call with TruistFebruary 8, 2025 | markets.businessinsider.comTruist maintains Buy on Protagonist Therapeutics with $60 targetFebruary 8, 2025 | msn.comProtagonist Therapeutics (NASDAQ:PTGX) Earns Market Outperform Rating from JMP SecuritiesJMP Securities reaffirmed a "market outperform" rating and set a $58.00 price target on shares of Protagonist Therapeutics in a report on Friday.February 7, 2025 | marketbeat.comProtagonist Therapeutics' (PTGX) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reiterated a "buy" rating and set a $50.00 price objective on shares of Protagonist Therapeutics in a research report on Friday.February 7, 2025 | marketbeat.comJMP Securities maintains PTGX stock with $58 targetFebruary 7, 2025 | msn.comProtagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $53.00JPMorgan Chase & Co. raised their price target on Protagonist Therapeutics from $51.00 to $53.00 and gave the stock an "overweight" rating in a research note on Tuesday.February 4, 2025 | marketbeat.comMoody Aldrich Partners LLC Decreases Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Moody Aldrich Partners LLC reduced its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 43.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 67,415 shares of the company's stock after selling 51,January 29, 2025 | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Trading 5.6% Higher - Time to Buy?Protagonist Therapeutics (NASDAQ:PTGX) Stock Price Up 5.6% - Here's What HappenedJanuary 27, 2025 | marketbeat.comPacer Advisors Inc. Buys 142,376 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Pacer Advisors Inc. lifted its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 8.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,876,466 shares of the company's stock after acquiring an additional 142,376January 27, 2025 | marketbeat.comInspire Investing LLC Decreases Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Inspire Investing LLC cut its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 71.1% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,555 shares of the company's stock after selliJanuary 26, 2025 | marketbeat.comJefferies maintains Buy on Protagonist Therapeutics, $57 targetJanuary 23, 2025 | msn.comAssenagon Asset Management S.A. Invests $2.02 Million in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Assenagon Asset Management S.A. acquired a new stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 52,239 shares of the company'sJanuary 23, 2025 | marketbeat.comProtagonist Therapeutics CFO Ali Asif reports stock saleJanuary 17, 2025 | msn.comProtagonist Therapeutics chief medical officer sells shares for tax obligationsJanuary 17, 2025 | msn.comProtagonist Therapeutics (NASDAQ:PTGX) Shares Down 6.2% - Time to Sell?Protagonist Therapeutics (NASDAQ:PTGX) Trading Down 6.2% - Should You Sell?January 16, 2025 | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Trading 8.9% Higher - Time to Buy?Protagonist Therapeutics (NASDAQ:PTGX) Trading 8.9% Higher - Here's WhyJanuary 15, 2025 | marketbeat.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Average Recommendation of "Buy" from AnalystsShares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) have earned a consensus recommendation of "Buy" from the nine research firms that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a hold rating, seven have issued a buy rating and onJanuary 15, 2025 | marketbeat.comProtagonist: Rusfertide PV Data Q1 2025 Isn't The Only 2025 Catalyst On DeckJanuary 13, 2025 | seekingalpha.comProtagonist Therapeutics (NASDAQ:PTGX) Trading Down 4.4% - What's Next?Protagonist Therapeutics (NASDAQ:PTGX) Trading Down 4.4% - What's Next?January 6, 2025 | marketbeat.comPrincipal Financial Group Inc. Purchases 310,804 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Principal Financial Group Inc. raised its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 3,099.4% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 320,832 shares of the company's stock after acquiring an additioDecember 29, 2024 | marketbeat.comJane Street Group LLC Decreases Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Jane Street Group LLC trimmed its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 74.0% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 32,858 shares of the company's stock after selliDecember 28, 2024 | marketbeat.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Acquired by Franklin Resources Inc.Franklin Resources Inc. lifted its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 127.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 81,591 shares of the company's stock afterDecember 25, 2024 | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Shares Down 2.3% - Here's What HappenedProtagonist Therapeutics (NASDAQ:PTGX) Stock Price Down 2.3% - Should You Sell?December 24, 2024 | marketbeat.comBarclays PLC Grows Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Barclays PLC boosted its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 223.6% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 126,995 shares of the company's stock after acquiring an additioDecember 21, 2024 | marketbeat.comHighTower Advisors LLC Lowers Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)HighTower Advisors LLC reduced its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 54.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 10,887 shares of the coDecember 21, 2024 | marketbeat.comWellington Management Group LLP Makes New Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Wellington Management Group LLP bought a new stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 30,079 shares of the company's stoDecember 20, 2024 | marketbeat.comTeachers Retirement System of The State of Kentucky Makes New Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Teachers Retirement System of The State of Kentucky acquired a new stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 20,200 shares of tDecember 19, 2024 | marketbeat.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by Y Intercept Hong Kong LtdY Intercept Hong Kong Ltd lowered its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 89.1% in the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 5,251 shares of the company's stock after selling 42,876 shares during the period. YDecember 19, 2024 | marketbeat.comState Street Corp Has $143.26 Million Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)State Street Corp grew its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 52.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,183,542 shares of the company's stock after purchasingDecember 14, 2024 | marketbeat.com14,801 Shares in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Purchased by XTX Topco LtdXTX Topco Ltd acquired a new position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) in the third quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 14,801 shares of the company's stock, valued at approximately $666,000. A number of otherDecember 13, 2024 | marketbeat.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Acquired by BNP Paribas Financial MarketsBNP Paribas Financial Markets boosted its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 448.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 20,294 shares of the company's stock after puDecember 12, 2024 | marketbeat.comPromising Prospects for Protagonist Therapeutics: Buy Rating Affirmed on Rusfertide’s Efficacy and Competitive EdgeDecember 11, 2024 | markets.businessinsider.comOptimistic Buy Rating for Protagonist Therapeutics Driven by Promising Rusfertide Data and Strategic Takeda PartnershipDecember 11, 2024 | markets.businessinsider.comProtagonist Therapeutics' (PTGX) Buy Rating Reiterated at HC WainwrightHC Wainwright restated a "buy" rating and set a $50.00 target price on shares of Protagonist Therapeutics in a research report on Tuesday.December 10, 2024 | marketbeat.comFmr LLC Purchases 19,737 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Fmr LLC grew its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 4.5% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 454,196 shares of the company's stock after acquiring an additional 19,737 shares during theDecember 10, 2024 | marketbeat.comProtagonist Therapeutics announces data from REVIVE study at ASHDecember 10, 2024 | markets.businessinsider.comWeiss Asset Management LP Takes Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Weiss Asset Management LP acquired a new stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 62,463 shares of the company's stock, valued at aDecember 8, 2024 | marketbeat.comPoint72 Asset Management L.P. Cuts Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Point72 Asset Management L.P. decreased its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 76.4% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 214,872 shares of the company'sDecember 8, 2024 | marketbeat.comBMO Capital Initiates Coverage of Protagonist Therapeutics (PTGX) with Outperform RecommendationDecember 6, 2024 | msn.com Get Protagonist Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter. Email Address PTGX Media Mentions By Week PTGX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PTGX News Sentiment▼0.700.60▲Average Medical News Sentiment PTGX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PTGX Articles This Week▼124▲PTGX Articles Average Week Get Protagonist Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Qiagen News Ascendis Pharma A/S News Roivant Sciences News Revolution Medicines News Legend Biotech News BridgeBio Pharma News Axsome Therapeutics News Blueprint Medicines News Telix Pharmaceuticals Limited American Depositary Shares News Elanco Animal Health News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PTGX) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagonist Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protagonist Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
